Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Jan;174(1):93-95.
doi: 10.7326/M20-6448. Epub 2020 Sep 25.

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Alice K Pau  1 , Judith Aberg  2 , Jason Baker  3 , Pamela S Belperio  4 , Craig Coopersmith  5 , Page Crew  1 , Birgit Grund  6 , Roy M Gulick  7 , Carly Harrison  8 , Arthur Kim  9 , H Clifford Lane  1 , Henry Masur  1 , Virginia Sheikh  10 , Kanal Singh  1 , Jinoos Yazdany  11 , Pablo Tebas  12 ; National Institutes of Health COVID-19 Treatment Guidelines Panel
Collaborators, Affiliations
Practice Guideline

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Alice K Pau et al. Ann Intern Med. 2021 Jan.

Abstract

In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-6448.

References

    1. National Institutes of Health. COVID-19 Treatment Guidelines. Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members. Accessed at www.covid19treatmentguidelines.nih.gov/panel-roster on 7 September 2020.
    1. U.S. Food and Drug Administration. Convalescent plasma letter of authorization. Accessed at www.fda.gov/media/141477/download on 6 September 2020.
    1. U.S. Food and Drug Administration. Emergency Use Authorization of Medical Products and Related Authorities: Guidance for Industry and Other Stakeholders. Accessed at www.fda.gov/media/97321/download on 31 August 2020.
    1. Fischer JC, Zänker K, van Griensven M, et al. The role of passive immunization in the age of SARS-CoV-2: an update. Eur J Med Res. 2020;25:16. [PMID: 32404189] doi:10.1186/s40001-020-00414-5 - PMC - PubMed
    1. Centers for Disease Control and Prevention. ACIP Vaccine Recommendations and Guidelienes. Accessed at www.cdc.gov/vaccines/hcp/acip-recs/index.html on 7 September 2020.

Publication types